Business Context and Reporting Period
This Form 8-K Current Report was filed by NeuroBo Pharmaceuticals, Inc. (NRBO) on August 14, 2023, covering events occurring on August 10, 2023, and August 11, 2023. The filing primarily addresses significant changes in corporate leadership and board committee composition. The company is a Delaware corporation headquartered in Boston, Massachusetts, engaged in pharmaceutical research and development.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive appointments and employment terms.
Material Changes
- Executive Appointment: The Board appointed Hyung Heon Kim as Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer, effective August 11, 2023.
- Executive Departure: Joseph Hooker ceased serving as Interim CEO and related roles on August 11, 2023, following the termination of the engagement agreement with Korn Ferry US. The departure was not related to any disagreement with the company.
- Board Committee Changes: Mr. Kim resigned from the Compensation and Nominating and Corporate Governance Committees. New appointments were made to fill vacancies, including Mark A. Glickman to the Audit and Compensation Committees, and Na Yeon "Irene" Kim to the Nominating and Corporate Governance Committee.
Employment Terms and Related Party Transaction
The appointment of Mr. Kim constitutes a related party transaction as he is a Board member and previously served as General Counsel and Senior Vice President of Dong-A ST, which beneficially owns approximately 60% of the Company's outstanding common stock.
Employment Agreement Highlights:
- Term: Initial term of two years, automatically renewing for one-year periods unless notice is given.
- Compensation: Annual base salary of $450,000, reviewed annually. Eligible for annual incentive compensation targeted at 50% of base salary.
- Equity: Granted 625,064 restricted stock units (RSUs). Vesting schedule: 50% on the first anniversary, with the remainder vesting monthly over the subsequent 12 months.
- Change in Control: 100% of unvested RSUs vest immediately if a Change in Control occurs and the award is not assumed. Additional severance and accelerated vesting apply if termination occurs within specific windows surrounding a Change in Control.
- Severance: In the event of termination without cause or resignation for good reason, Mr. Kim is entitled to 50% of his then-current base salary plus six months of COBRA coverage, subject to a general release of claims.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the current beneficial ownership percentage of Dong-A ST to assess the scale of the related party transaction.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership transition.
- Monitor future filings for the impact of the new CEO on the company's operational strategy and financial outlook.